255 related articles for article (PubMed ID: 26261055)
1. Animal models of spontaneous pancreatic neuroendocrine tumors.
Yu R
Mol Cell Endocrinol; 2016 Feb; 421():60-7. PubMed ID: 26261055
[TBL] [Abstract][Full Text] [Related]
2. Animal models and cell lines of pancreatic neuroendocrine tumors.
Babu V; Paul N; Yu R
Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
[TBL] [Abstract][Full Text] [Related]
4. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
5. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.
Crippa S; Partelli S; Zamboni G; Scarpa A; Tamburrino D; Bassi C; Pederzoli P; Falconi M
Surgery; 2014 Jan; 155(1):145-53. PubMed ID: 24646958
[TBL] [Abstract][Full Text] [Related]
6. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
Cho CM
Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
8. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
[TBL] [Abstract][Full Text] [Related]
9. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
Chatani PD; Agarwal SK; Sadowski SM
Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
[TBL] [Abstract][Full Text] [Related]
10. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
Andersen KØ; Detlefsen S; Brusgaard K; Christesen HT
Front Endocrinol (Lausanne); 2024; 15():1351624. PubMed ID: 38868744
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
[TBL] [Abstract][Full Text] [Related]
12. Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors.
Zhou H; Chen Q; Tan W; Qiu Z; Li S; Song Y; Gao S
Gene; 2017 Aug; 625():72-77. PubMed ID: 28479381
[TBL] [Abstract][Full Text] [Related]
13. The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan.
Ito T; Lee L; Hijioka M; Kawabe K; Kato M; Nakamura K; Ueda K; Ohtsuka T; Igarashi H
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):574-7. PubMed ID: 25689058
[TBL] [Abstract][Full Text] [Related]
14. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.
Zhu LM; Tang L; Qiao XW; Wolin E; Nissen NN; Dhall D; Chen J; Shen L; Chi Y; Yuan YZ; Ben QW; Lv B; Zhou YR; Bai CM; Chen J; Song YL; Song TT; Lu CM; Yu R; Chen YJ
Medicine (Baltimore); 2016 Feb; 95(7):e2836. PubMed ID: 26886644
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.
Yu R; Dhall D; Nissen NN; Zhou C; Ren SG
PLoS One; 2011; 6(8):e23397. PubMed ID: 21853126
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic diagnosis and treatment of pancreatic neuroendocrine tumors.
Rustagi T; Farrell JJ
J Clin Gastroenterol; 2014; 48(10):837-44. PubMed ID: 24828360
[TBL] [Abstract][Full Text] [Related]
17. Genetics of Pancreatic Neuroendocrine Tumors.
Mohindroo C; McAllister F; De Jesus-Acosta A
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
[TBL] [Abstract][Full Text] [Related]
19. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
[TBL] [Abstract][Full Text] [Related]
20. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
